

Jordan Lerner-Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8945518/publications.pdf>

Version: 2024-02-01

44
papers

1,415
citations

623734

14
h-index

345221

36
g-index

46
all docs

46
docs citations

46
times ranked

3227
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. <i>BMJ Open</i> , 2022, 8, e021876.	1.9	22
2	Widening the lens of actionability: A qualitative study of primary care providers' views and experiences of managing secondary genomic findings. <i>European Journal of Human Genetics</i> , 2022, 30, 595-603.	2.8	10
3	Data sharing to improve concordance in variant interpretation across laboratories: results from the Canadian Open Genetics Repository. <i>Journal of Medical Genetics</i> , 2022, 59, 571-578.	3.2	14
4	Challenges and practical solutions for managing secondary genomic findings in primary care. <i>European Journal of Medical Genetics</i> , 2022, 65, 104384.	1.3	4
5	Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003082.	2.5	0
6	Principles of molecular testing for hereditary cancer. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 356-381.	2.8	5
7	Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery. <i>BMJ Open</i> , 2022, 12, e060899.	1.9	10
8	A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings. <i>Human Genetics</i> , 2022, 141, 1875-1885.	3.8	1
9	Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study. <i>Journal of Medical Genetics</i> , 2021, 58, 275-283.	3.2	14
10	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 242-252.	2.8	12
11	Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings. <i>Human Genetics</i> , 2021, 140, 493-504.	3.8	13
12	Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 871-879.	2.5	7
13	The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. <i>Genetics in Medicine</i> , 2021, 23, 1086-1094.	2.4	18
14	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. <i>Gynecologic Oncology</i> , 2021, 161, 221-227.	1.4	9
15	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, e22525-e22525.	1.6	0
16	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. <i>Cancer</i> , 2021, 127, 3082-3091.	4.1	6
17	Implementation of serological and molecular tools to inform COVID-19 patient management: protocol for the GENCOV prospective cohort study. <i>BMJ Open</i> , 2021, 11, e052842.	1.9	6
18	Patient and public preferences for being recontacted with updated genomic results: a mixed methods study. <i>Human Genetics</i> , 2021, 140, 1695-1708.	3.8	3

#	ARTICLE	IF	CITATIONS
19	Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. <i>Genetics in Medicine</i> , 2020, 22, 727-735.	2.4	34
20	Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel. <i>Journal of Medical Genetics</i> , 2020, 57, 380-384.	3.2	10
21	Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. <i>Cancers</i> , 2020, 12, 3468.	3.7	12
22	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. <i>Cancer</i> , 2020, 126, 4886-4894.	4.1	15
23	Quality of life drives patients' preferences for secondary findings from genomic sequencing. <i>European Journal of Human Genetics</i> , 2020, 28, 1178-1186.	2.8	14
24	Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1951-1958.	2.5	5
25	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 398-403.	6.4	25
26	Variant classification changes over time in BRCA1 and BRCA2. <i>Genetics in Medicine</i> , 2019, 21, 2248-2254.	2.4	37
27	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e031092.	1.9	10
28	Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 1577-1577.	1.6	1
29	The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. <i>European Journal of Human Genetics</i> , 2018, 26, 984-995.	2.8	42
30	Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). <i>Genetics in Medicine</i> , 2018, 20, 294-302.	2.4	27
31	Reply to "Mutations in RECQL are not associated with breast cancer risk in an Australian population". <i>Nature Genetics</i> , 2018, 50, 1348-1349.	21.4	2
32	Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol. <i>BMJ Open</i> , 2018, 8, e025317.	1.9	3
33	A high frequency of PALB2 mutations in Jamaican patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 591-596.	2.5	8
34	Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. <i>Modern Pathology</i> , 2017, 30, 1748-1759.	5.5	72
35	PALB2 mutations in high-risk women with breast or ovarian cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1527-1527.	1.6	2
36	Molecular-based classification algorithm for endometrial carcinoma to categorize ovarian endometrioid carcinoma into prognostically significant groups. <i>Journal of Clinical Oncology</i> , 2017, 35, e17081-e17081.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Genetic testing for Lynch syndrome in the province of Ontario. <i>Cancer</i> , 2016, 122, 1672-1679.	4.1	12
38	Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations. <i>Journal of Medical Genetics</i> , 2015, 52, 438-445.	3.2	27
39	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. <i>Nature Genetics</i> , 2015, 47, 257-262.	21.4	306
40	Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1315-1326.	2.4	42
41	Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2015, 148, 556-564.	1.3	256
42	Identification of a novel MSH6 germline variant in a family with multiple gastro-intestinal malignancies by next generation sequencing. <i>Familial Cancer</i> , 2015, 14, 69-75.	1.9	1
43	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. <i>Cancer</i> , 2014, 120, 3932-3939.	4.1	114
44	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. <i>European Journal of Cancer</i> , 2014, 50, 987-996.	2.8	180